May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Diagnosis and Management of Biopsy-Proven Ocular Sarcoidosis in France
Author Affiliations & Notes
  • T. Grenet
    Pitié-Salpêtrière Hospital, Paris, France
    Ophthalmology,
  • C. Chapelon
    Pitié-Salpêtrière Hospital, Paris, France
    Internal Medicine,
  • J.-C. Piette
    Pitié-Salpêtrière Hospital, Paris, France
    Internal Medicine,
  • G. Ducos
    Pitié-Salpêtrière Hospital, Paris, France
    Ophthalmology,
  • N. Cassoux
    Pitié-Salpêtrière Hospital, Paris, France
    Ophthalmology,
  • C. Fardeau
    Pitié-Salpêtrière Hospital, Paris, France
    Ophthalmology,
  • P. LeHoang
    Pitié-Salpêtrière Hospital, Paris, France
    Ophthalmology,
  • B. Bodaghi
    Pitié-Salpêtrière Hospital, Paris, France
    Ophthalmology,
  • Footnotes
    Commercial Relationships T. Grenet, None; C. Chapelon, None; J. Piette, None; G. Ducos, None; N. Cassoux, None; C. Fardeau, None; P. LeHoang, None; B. Bodaghi, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5155. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Grenet, C. Chapelon, J.-C. Piette, G. Ducos, N. Cassoux, C. Fardeau, P. LeHoang, B. Bodaghi; Diagnosis and Management of Biopsy-Proven Ocular Sarcoidosis in France. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5155.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To describe clinical features and paraclinical findings in patients managed for biopsy-proven ocular sarcoidosis at Pitié-Salpêtrière Hospital, Paris, France.

Methods:: Clinical presentation, angiographic features, laboratory investigations, treatment strategies and visual outcome of patients managed between 2000 and 2005 for biopsy-proven ocular sarcoidosis at Pitie-Salpetriere Hospital were retrospectively reviewed.

Results:: Among 3740 patients referred for the management of a first episode of uveitis, we identified 210 patients (5.6%) with presumed ocular sarcoidosis and 53 patients (20 M and 33 F) with biopsy-proven ocular sarcoidosis (1.4%). Mean age at diagnosis was 41.8 years (range 11-80 y). Most of patients were Caucasian (55%). Granulomatous panuveitis was present in 59% of cases followed by posterior uveitis (24%), anterior or intermediate uveitis (10%) and other forms of ocular inflammation in 7% of cases. Abnormal laboratory findings included : serum angiotensin converting enzyme (79.5%) and lysozyme (88.6%), chest CT-scan (83.3%), bronchoalveolar lavage (77.8%), gallium-scan (72%) and negative PPD (80%). Extraocular manifestations of sarcoidosis were diagnosed in 84.9% of patients, including pulmonary and neurological involvement in most of the cases. Histological confirmation was performed based on bronchoalveolar biopsy (40%); salivary gland biopsy (24%); cutaneous biopsy (9%) or other types (27%). Corticosteroids were used in 84.5% of cases and immunosuppressors were mandatory in 41% of cases. Methotrexate (40.9%) and azathioprine (22.7%) were the most commonly used drugs. Ocular complications occurred in 37.7% of cases, including macular edema (24.5%), choroidal neovascularisation (3.7%) and inflammatory retinal vein occlusion with secondary neovascular glaucoma (3.1%). Final visual acuity was improved or stabilized in most of patients (86%) with a mean follow-up of 36.3 months (range 1-204 months)Discussion: Biopsy-proven ocular sarcoidosis remains a rare cause of chronic uveitis in France. Corticosteroids remain the mainstay of treatment with a good visual outcome in most of cases. Despite the absence of histological evidences, the management of presumed ocular sarcoidosis is based on a similar strategy.

Keywords: uveitis-clinical/animal model • inflammation • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×